← FDA DRUG APPROVALS

FDA ANDA · ANDA201464

LEVETIRACETAM

Sponsor: PHARMADAX

APPLICATION
ANDA201464
TYPE
ANDA
ORIGINAL APPROVAL
2012-05-25
LATEST ACTION
2024-11-14
ROUTE
ORAL
DOSAGE FORM
TABLET, EXTENDED RELEASE
MARKETING STATUS
Discontinued

Products

LEVETIRACETAMDiscontinued
LEVETIRACETAM 500MG · TABLET, EXTENDED RELEASE · ORAL
LEVETIRACETAMDiscontinued
LEVETIRACETAM 750MG · TABLET, EXTENDED RELEASE · ORAL

Approval history

2024-11-14Labeling · Supplement 12 · standardAP
2024-01-25Labeling · Supplement 11 · standardAP
2021-10-01Labeling · Supplement 3 · standardAP
2012-05-25Not Applicable · OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →